Valion Bio (VBIO) Non-Current Deffered Revenue (2024 - 2025)
Valion Bio (VBIO) posted Non-Current Deffered Revenue of $301000.0 for Q2 2025, up 77.06% on a QoQ basis from $170000.0 in Q1 2025.
Powered by 
Analysis
Valion Bio (VBIO) Non-Current Deffered Revenue (2024 - 2025) Analysis & Trends
Valion Bio has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $301000.0 in Q2 2025.
- On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $301000.0 in Q2 2025; TTM through Jun 2025 was $301000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $49000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue was $301000.0 for Q2 2025 at Valion Bio, up from $170000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $301000.0 in Q2 2025, with the low at $49000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 220.40 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 147.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Valion Bio | 298,792.01 | -1.90 Mn | -45,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 301,000.00 |
| Mar 31, 2025 | 170,000.00 |
| Dec 31, 2024 | 49,000.00 |
| Sep 30, 2024 | 112,000.00 |